Pharmaceuticals: Pakistan Listed Pharma Sector Analysis 2024 Deregulation improved sales and margins - By Topline Research

<p></p><ul><li><span style="font-family:Arial, Helvetica, sans-serif;font-size:medium;">Pakistan listed pharmaceuticals sector&rsquo;s earnings were up 3.1x to Rs24.8bn in calendar year 2024. This jump in profitability is primarily attributed to higher net sales and improved gross margins.</span></li></ul><ul><li><span style="font-family:Arial, Helvetica, sans-serif;font-size:medium;">Net sales increased by 15% YoY to Rs318bn in 2024, primarily driven by a increase in drug prices.</span></li></ul><ul><li><span style="font-family:Arial, Helvetica, sans-serif;font-size:medium;">To recall, in Feb-2024 the government approved the deregulation of non-essential drug prices, which allowed companies to increase prices without any cap as it was under previous drug policy to increase the prices of all other non-essential drugs by up to the full ...